On October 8, GENSCRIPT BIO fell 3.22% in regular trading, trading at HK$41.44 with a turnover of HK$78.392 million. The stock extended weakness following a sharp 12.70% drop in the previous session, reflecting broader correction pressure across the pharmaceutical sector.

The pullback was amplified by overnight weakness in US pharmaceutical stocks, after Allist Pharmaceuticals' furmonertinib failed a global Phase 3 trial, sending its shares down 46.98% and weighing on sentiment across Hong Kong's biotech complex. GENSCRIPT BIO had surged nearly 270% from early July to October 6, and some institutions moved to lock in profits at elevated levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)